GlassScriptPhysician profile
Michael C Balduzzi
NPI 1346565934
$10,379.36
in general payments reported to CMS, 2019-2025
40 companies · $2,003 in 2025
The $2,003 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,511 · 2020: $779 · 2021: $1,457 · 2022: $1,370 · 2023: $1,730 · 2024: $1,530 · 2025: $2,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,182 · Education: $61.08 · Consulting Fee: $19.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,181.78 |
| Education | $61.08 |
| Consulting Fee | $19.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,828.57 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $833.12 | 2019-2025 | |
| Octapharma USA, INC. | $821.82 | 2019-2024 | Cutaquig |
| Takeda Pharmaceuticals U.S.A., INC. | $800.37 | 2020-2025 | Takhzyro, Hyqvia, Glassia |
| Csl Behring | $616.84 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $572.11 | 2021-2025 | Dupixent |
| Amgen INC. | $557.52 | 2020-2025 | Tezspire |
| Optinose US, INC. | $501.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $489.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $391.44 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Kaleo, INC. | $378.67 | 2019-2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $338.91 | 2019-2022 | |
| Pfizer INC. | $270.93 | 2020-2025 | |
| Greer Laboratories, INC. | $221.57 | 2019-2025 | Oralair |
| Grifols USA, LLC | $195.27 | 2023-2025 | Xembify, Prolastin-C Liquid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $179.84 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $169.88 | 2019-2025 | Ruconest |
| Shire North American Group INC | $159.24 | 2019 | |
| Genentech USA, INC. | $141.76 | 2022-2025 | Xolair |
| Abbvie INC. | $129.52 | 2021-2025 | Rinvoq |
| Incyte Corporation | $84.31 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.59 | 2022 | |
| Organon LLC | $70.67 | 2025 | Vtama |
| Baxter Healthcare | $64.01 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Adma Biomanufacturing LLC | $54.33 | 2022-2025 | |
| Blueprint Medicines Corporation | $51.09 | 2023-2024 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $50.46 | 2025 | Dawnzera |
| Ars Pharmaceuticals Operations, INC. | $49.42 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $46.71 | 2022 | |
| Alk-Abello, INC | $34.96 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $30.77 | 2019 | |
| Leo Pharma INC. | $29.33 | 2025 | Adbry |
| Kedrion Biopharma, INC. | $19.81 | 2024 | Kedrab, Koate, Gammaked |
| Kowa Pharmaceuticals America, INC. | $19.65 | 2025 | Zoryve |
| Circassia INC. | $19.28 | 2019 | |
| Sanofi Pasteur INC. | $19.20 | 2019 | |
| Philips North America LLC | $18.91 | 2020 | |
| Hospira, INC. | $18.31 | 2019 | |
| Seqirus USA INC | $12.39 | 2022 | |
| Advanced Respiratory, INC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Balduzzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.